These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25096504)

  • 1. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tao Y; Liang G
    Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.
    Zhu C; Wang G; Li J; Chen L; Wang C; Wang Y; Lin P; Ran H
    Neurol Res; 2014 Nov; 36(11):1028-34. PubMed ID: 24725292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis.
    Chen W; Wang H; Wei H; Gu S; Wei H
    J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
    Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
    BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
    Hauser RA; Hattori N; Fernandez H; Isaacson SH; Mochizuki H; Rascol O; Stocchi F; Li J; Mori A; Nakajima Y; Ristuccia R; LeWitt P
    J Parkinsons Dis; 2021; 11(4):1663-1675. PubMed ID: 34486986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
    Paton DM
    Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan.
    Takahashi M; Fujita M; Asai N; Saki M; Mori A
    Expert Opin Pharmacother; 2018 Oct; 19(15):1635-1642. PubMed ID: 30281377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of istradefylline for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Drug Saf; 2015 May; 14(5):769-75. PubMed ID: 25676023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
    Mizuno Y; Kondo T;
    Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Istradefylline for the treatment of Parkinson's disease.
    Park A; Stacy M
    Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occupancy of adenosine A
    Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K
    Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis.
    Wang XL; Feng ST; Chen B; Hu D; Wang ZZ; Zhang Y
    Neurosci Lett; 2022 Mar; 774():136515. PubMed ID: 35149201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study.
    Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of istradefylline in the Parkinson's disease armamentarium.
    Müller T
    Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of istradefylline for Parkinson's disease: A meta-analysis.
    Sako W; Murakami N; Motohama K; Izumi Y; Kaji R
    Sci Rep; 2017 Dec; 7(1):18018. PubMed ID: 29269791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease.
    Kondo T; Mizuno Y;
    Clin Neuropharmacol; 2015; 38(2):41-6. PubMed ID: 25768849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
    Müller T
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease.
    Yabe I; Kitagawa M; Takahashi I; Matsushima M; Sasaki H
    Clin Neuropharmacol; 2017; 40(6):261-263. PubMed ID: 28976411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.